A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients

Trial Profile

A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Radalbuvir (Primary) ; Vedroprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 17 Apr 2016 Results assessing Sofosbuvir-based therapy among patients with mental health disease from SPARE, SYNERGY-A and ERADICATE studies, spresented at The International Liver Congress™ 2016.
    • 17 Apr 2016 Results of an integrated analysis from five trials (n=236) presented at The International Liver Congress™ 2016
    • 01 Jan 2016 Results of pooled analysis of 2 phase II trials (NCT01805882 and NCT01878799) published in the AIDS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top